NIH VideoCast - Integrating Mass Spectrometry-based Proteomics and Lipidomics Reveals Biomarkers and Altered Signaling Pathways During Progressive Neurodegeneration in Niemann-Pick Disease, type C1

Skip Navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Integrating Mass Spectrometry-based Proteomics and Lipidomics Reveals Biomarkers and Altered Signaling Pathways During Progressive Neurodegeneration in Niemann-Pick Disease, type C1

Loading... Loading video...

91 Views

Air date:	Friday, February 8, 2019, 1:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 91 (17 Live, 74 On-demand)
Category:	Proteomics
Runtime:	00:48:26
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	Proteomics Interest Group Advances in mass spectrometry technology have enabled large-scale differential analysis of proteins and lipids to investigate altered pathways in human disease. Our laboratory studies Niemann-Pick Disease, type C1 (NPC1) a lysosomal storage disorder with visceral involvement and progressive cerebellar neurodegeneration. Using a combination of differential proteomics, lipidomics and mass spectrometry imaging, we have identified new candidate biomarkers in a mouse model of NPC1. These alterations now provide a basis for evaluation in NPC1 patients and also can be used for therapeutic development. Several examples will be presented. For more information go to http://proteome.nih.gov

Author:	Dr. Stephanie Cologna, University of Illinois at Chicago

CIT Live ID:	31416
Permanent link:	https://videocast.nih.gov/watch=31416

Related Videos...